Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [2] - The company is working on next-generation molecules that modulate G-protein coupled receptors, aiming to create first-in-class therapeutics with clinical and commercial differentiation [2] Clinical Trials - Skye is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, specifically targeting obesity [2] - The trial is also evaluating the combination of nimacimab with a GLP-1R agonist, Wegovy® [2] Investor Engagement - Skye will participate in the BIO CEO & Investor Conference on February 10, 2025, focusing on obesity treatments [1] - The company will also present a corporate overview at the Oppenheimer 35th Healthcare Life Sciences Conference on February 12, 2025 [1]
Skye Bioscience Announces Participation in February Conferences